MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024

Rhea-AI Summary

MaxCyte, Inc. announced the release of financial results for the first quarter of 2024, scheduled after the U.S. market close on May 7th, 2024. The company, a cell-engineering focused organization, aims to advance cell therapeutics and bioprocessing applications. Investors can join the earnings conference call hosted by the management at 4:30 p.m. Eastern Time.

ROCKVILLE, Md., April 10, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioprocessing applications, today announced that it will release financial results for the first quarter 2024 after the U.S. market close on Tuesday, May 7th, 2024. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time.

Earnings Conference Call Details
Investors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advance. A live and archived webcast of the event will be available on the “Events” section of the MaxCyte website at https://investors.maxcyte.com/.

About MaxCyte
At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients’ lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today’s processes to innovate tomorrow’s solutions. Our ExPERT™ platform, which is based on our Flow Electroporation^® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology, as well as scientific, technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at maxcyte.com and follow us on X (formerly Twitter) and LinkedIn.

MaxCyte Contacts: 
US IR Adviser 
Gilmartin Group 
David Deuchler, CFA 
+1 415-937-5400 
ir@maxcyte.com

US Media Relations 
Spectrum Seismic Collaborative 
Valerie Enes 
+1 408-497-8568 
venes@spectrumscience.com 

Nominated Adviser and Joint Corporate Broker 
Panmure Gordon 
Emma Earl / Freddy Crossley 
Corporate Broking 
Rupert Dearden 
+44 (0)20 7886 2500 

UK IR Adviser 
ICR Consilium
Mary-Jane Elliott 
Chris Welsh 
+44 (0)203 709 5700
maxcyte@consilium-comms.com

FAQ

When will MaxCyte, Inc. release financial results for the first quarter of 2024?

MaxCyte, Inc. will release financial results for the first quarter of 2024 after the U.S. market close on Tuesday, May 7th, 2024.

What is the focus of MaxCyte, Inc. as mentioned in the press release?

MaxCyte, Inc. is a cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and innovative bioprocessing applications.

When will the conference call to discuss financial results take place?

The conference call to discuss financial results will take place at 4:30 p.m. Eastern Time.

How can investors listen to the conference call?

Investors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advance.

Where can a live and archived webcast of the event be accessed?

A live and archived webcast of the event will be available on the 'Events' section of the MaxCyte website at https://investors.maxcyte.com/.